Pacira Pharmaceuticals (PCRX) PT Raised to $34.00

Pacira Pharmaceuticals (NASDAQ:PCRX) had its price target upped by investment analysts at Canaccord Genuity from $32.00 to $34.00 in a research report issued on Monday, Marketbeat Ratings reports. The firm currently has a “hold” rating on the stock. Canaccord Genuity’s price objective indicates a potential upside of 1.64% from the company’s previous close.

Several other brokerages have also recently commented on PCRX. ValuEngine upgraded Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. HC Wainwright set a $55.00 target price on Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, January 4th. BMO Capital Markets decreased their target price on Pacira Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a report on Thursday, March 1st. BidaskClub cut Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. Finally, JPMorgan Chase restated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and eight have issued a buy rating to the company’s stock. Pacira Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $44.35.

NASDAQ:PCRX traded down $1.10 during trading hours on Monday, reaching $33.45. The company had a trading volume of 1,628,686 shares, compared to its average volume of 1,212,933. Pacira Pharmaceuticals has a one year low of $26.95 and a one year high of $52.47. The company has a current ratio of 6.96, a quick ratio of 6.22 and a debt-to-equity ratio of 0.99.



Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Wednesday, February 28th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.46. The company had revenue of $79.08 million for the quarter, compared to analysts’ expectations of $79.06 million. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.09 earnings per share. sell-side analysts predict that Pacira Pharmaceuticals will post -0.51 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. HealthCor Management L.P. lifted its stake in shares of Pacira Pharmaceuticals by 8.6% during the fourth quarter. HealthCor Management L.P. now owns 2,800,000 shares of the company’s stock valued at $127,820,000 after acquiring an additional 221,960 shares during the period. Consonance Capital Management LP lifted its stake in shares of Pacira Pharmaceuticals by 16.1% during the fourth quarter. Consonance Capital Management LP now owns 1,602,334 shares of the company’s stock valued at $73,147,000 after acquiring an additional 222,200 shares during the period. Macquarie Group Ltd. lifted its stake in shares of Pacira Pharmaceuticals by 9.7% during the fourth quarter. Macquarie Group Ltd. now owns 1,266,414 shares of the company’s stock valued at $57,812,000 after acquiring an additional 111,869 shares during the period. Rock Springs Capital Management LP lifted its stake in shares of Pacira Pharmaceuticals by 1.7% during the fourth quarter. Rock Springs Capital Management LP now owns 1,106,700 shares of the company’s stock valued at $50,521,000 after acquiring an additional 18,700 shares during the period. Finally, Stephens Investment Management Group LLC lifted its stake in shares of Pacira Pharmaceuticals by 0.9% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,016,366 shares of the company’s stock valued at $46,397,000 after acquiring an additional 9,266 shares during the period.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://dakotafinancialnews.com/2018/04/10/canaccord-genuity-analysts-give-pacira-pharmaceuticals-pcrx-a-34-00-price-target.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply